TP53 and acute lymphoblastic leukemia: Kanagal-Shamanna et al. reported TP53 mutation in approximately 15% of newly diagnosed adult ALL patients with a significant association with low-hypodiploid karyotype but not with survival and CR duration after frontline treatment with HCVAD-based regimens.